Published in Kidney Blood Press Res on March 02, 2010
Strategies to overcome the ABO barrier in kidney transplantation. Nat Rev Nephrol (2015) 0.78
The Effect of Mycophenolate Mofetil on Early Wound Healing in a Rodent Model. Transplant Direct (2016) 0.75
Symptomatic lymphocele developing soon after acute renal allograft rejection: coincidental or causal connection? Clin Kidney J (2013) 0.75
Relationship between Post-kidney Transplantation Antithymocyte Globulin Therapy and Wound Healing Complications. Int J Organ Transplant Med (2012) 0.75
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med (2015) 18.66
Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med (2013) 7.54
Everolimus in patients with autosomal dominant polycystic kidney disease. N Engl J Med (2010) 5.50
Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA (2012) 5.27
Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet (2003) 3.70
Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int (2003) 3.54
EBPG on Vascular Access. Nephrol Dial Transplant (2007) 3.26
EBPG guideline on nutrition. Nephrol Dial Transplant (2007) 2.68
Vitamin D status and clinical outcomes in incident dialysis patients: results from the NECOSAD study. Nephrol Dial Transplant (2010) 2.64
Treatment of Fabry disease with different dosing regimens of agalsidase: effects on antibody formation and GL-3. Mol Genet Metab (2008) 2.60
Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry. Mol Genet Metab (2007) 2.51
Lipid-lowering therapy in persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med (2012) 2.51
Laparoscopic versus open adrenalectomy for adrenocortical carcinoma: surgical and oncologic outcome in 152 patients. Eur Urol (2010) 2.49
Vitamin D reduces left atrial volume in patients with left ventricular hypertrophy and chronic kidney disease. Am Heart J (2012) 2.42
Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study. Circulation (2003) 2.22
Expert opinion on temporary treatment recommendations for Fabry disease during the shortage of enzyme replacement therapy (ERT). Mol Genet Metab (2010) 2.13
Oxidative stress in end-stage renal disease: an emerging threat to patient outcome. Nephrol Dial Transplant (2003) 2.10
Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment. Circulation (2009) 2.07
Predicting mortality in incident dialysis patients: an analysis of the United Kingdom Renal Registry. Am J Kidney Dis (2011) 2.01
EBPG guideline on dialysis strategies. Nephrol Dial Transplant (2007) 1.90
The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. Am J Cardiol (2008) 1.88
Fabry disease: guidelines for the evaluation and management of multi-organ system involvement. Genet Med (2006) 1.87
Etiology of the protein-energy wasting syndrome in chronic kidney disease: a consensus statement from the International Society of Renal Nutrition and Metabolism (ISRNM). J Ren Nutr (2013) 1.85
EAU guidelines on vesicoureteral reflux in children. Eur Urol (2012) 1.76
Expression of microRNA-221 is progressively reduced in aggressive prostate cancer and metastasis and predicts clinical recurrence. Int J Cancer (2010) 1.76
Tumor growth in urinary diversion: a multicenter analysis. Eur Urol (2011) 1.74
Vitamin D deficiency is associated with sudden cardiac death, combined cardiovascular events, and mortality in haemodialysis patients. Eur Heart J (2010) 1.72
Impact of enzyme replacement therapy on cardiac morphology and function and late enhancement in Fabry's cardiomyopathy. Am J Cardiol (2006) 1.71
Geographic differences in genetic susceptibility to IgA nephropathy: GWAS replication study and geospatial risk analysis. PLoS Genet (2012) 1.69
Association of eGFR-Related Loci Identified by GWAS with Incident CKD and ESRD. PLoS Genet (2011) 1.68
EBPG guideline on haemodynamic instability. Nephrol Dial Transplant (2007) 1.65
The efferent segment in continent cutaneous urinary diversion: a comprehensive review of the literature. BJU Int (2011) 1.59
The challenge of sudden death in dialysis patients. Clin J Am Soc Nephrol (2008) 1.52
Last resort in devastated bladder outlet: bladder neck closure and continent vesicostomy--long-term results and comparison of different techniques. Urology (2010) 1.49
Prospective randomized trial comparing flutamide as adjuvant treatment versus observation after radical prostatectomy for locally advanced, lymph node-negative prostate cancer. Eur Urol (2004) 1.47
Nephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy. Nephrol Dial Transplant (2008) 1.46
Prognostic value of perinodal lymphovascular invasion following radical cystectomy for lymph node-positive urothelial carcinoma. Eur Urol (2012) 1.46
Apolipoprotein E genotype predicts cardiovascular endpoints in dialysis patients with type 2 diabetes mellitus. Atherosclerosis (2009) 1.45
Tei index in fabry disease. J Am Soc Echocardiogr (2011) 1.44
OPPORTUNITY™: a large-scale randomized clinical trial of growth hormone in hemodialysis patients. Nephrol Dial Transplant (2011) 1.44
Impact of oxidized low density lipoprotein on vascular cells. Atherosclerosis (2005) 1.43
The effect of fluvastatin on cardiac outcomes in patients with moderate to severe renal insufficiency: a pooled analysis of double-blind, randomized trials. Int J Cardiol (2006) 1.43
Endothelial progenitor cells in patients on extracorporeal maintenance dialysis therapy. Nephrol Dial Transplant (2010) 1.41
Radical cystectomy--often too late? 1987. Eur Urol (2006) 1.38
Reduction of elevated plasma globotriaosylsphingosine in patients with classic Fabry disease following enzyme replacement therapy. Biochim Biophys Acta (2010) 1.35
Reverse epidemiology in systolic and nonsystolic heart failure: cumulative prognostic benefit of classical cardiovascular risk factors. Circ Heart Fail (2009) 1.35
Inflammation and outcome in end-stage renal failure: does female gender constitute a survival advantage? Kidney Int (2002) 1.33
The variation of morphological and functional cardiac manifestation in Fabry disease: potential implications for the time course of the disease. Eur Heart J (2005) 1.32
Understanding competing risks: a simulation point of view. BMC Med Res Methodol (2011) 1.31
Identification of a new tumor suppressor gene located at chromosome 8p21.3-22. FASEB J (2003) 1.31
Prevention and treatment of protein energy wasting in chronic kidney disease patients: a consensus statement by the International Society of Renal Nutrition and Metabolism. Kidney Int (2013) 1.31
The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient. Diab Vasc Dis Res (2008) 1.27
Factors influencing the decision to start renal replacement therapy: results of a survey among European nephrologists. Am J Kidney Dis (2012) 1.26
Cross-talk between the kidney and the cardiovascular system. J Am Soc Nephrol (2006) 1.25
Carbamylation of serum albumin as a risk factor for mortality in patients with kidney failure. Sci Transl Med (2013) 1.25
Native C-reactive protein increases whereas modified C-reactive protein reduces atherosclerosis in apolipoprotein E-knockout mice. Circulation (2005) 1.24
Timing and outcome of renal replacement therapy in patients with congenital malformations of the kidney and urinary tract. Clin J Am Soc Nephrol (2012) 1.24
Copeptin levels associate with cardiovascular events in patients with ESRD and type 2 diabetes mellitus. J Am Soc Nephrol (2011) 1.23
Rationale and trial design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON). Am J Nephrol (2013) 1.23
Effects of comorbid and demographic factors on dialysis modality choice and related patient survival in Europe. Nephrol Dial Transplant (2011) 1.23
Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation. Nephrol Dial Transplant (2011) 1.23
End-stage renal disease in patients with Fabry disease: natural history data from the Fabry Registry. Nephrol Dial Transplant (2009) 1.22
Residual macrovascular risk in 2013: what have we learned? Cardiovasc Diabetol (2014) 1.20
Atorvastatin and low-density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis. Clin J Am Soc Nephrol (2011) 1.19
Recommendations and guidelines for the diagnosis and treatment of Fabry nephropathy in adults. Nat Clin Pract Nephrol (2008) 1.19
Distinct microRNA expression profile in prostate cancer patients with early clinical failure and the impact of let-7 as prognostic marker in high-risk prostate cancer. PLoS One (2013) 1.17
Association between plasma triglycerides and high-density lipoprotein cholesterol and microvascular kidney disease and retinopathy in type 2 diabetes mellitus: a global case-control study in 13 countries. Circulation (2013) 1.13
Bone alkaline phosphatase and mortality in dialysis patients. Clin J Am Soc Nephrol (2011) 1.13
Advanced glycation end products and mortality in hemodialysis patients. Kidney Int (2002) 1.12
Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™). Cardiovasc Diabetol (2014) 1.12
Lipid management in chronic kidney disease: synopsis of the Kidney Disease: Improving Global Outcomes 2013 clinical practice guideline. Ann Intern Med (2014) 1.11
Glycemic control and cardiovascular events in diabetic hemodialysis patients. Circulation (2009) 1.10
The 2008 ERA-EDTA Registry Annual Report-a précis. NDT Plus (2010) 1.10
The German Chronic Kidney Disease (GCKD) study: design and methods. Nephrol Dial Transplant (2011) 1.09
Lack of endothelial nitric oxide synthase promotes endothelin-induced hypertension: lessons from endothelin-1 transgenic/endothelial nitric oxide synthase knockout mice. J Am Soc Nephrol (2007) 1.07
Baseline characteristics in the Bardoxolone methyl EvAluation in patients with Chronic kidney disease and type 2 diabetes mellitus: the Occurrence of renal eveNts (BEACON) trial. Nephrol Dial Transplant (2013) 1.07
Patients with Fabry disease after enzyme replacement therapy dose reduction versus treatment switch. J Am Soc Nephrol (2014) 1.07
Continent cutaneous urinary diversion: long-term follow-up of more than 800 patients with ileocecal reservoirs. World J Urol (2006) 1.07
Electrocardiography and outcome in patients with diabetes mellitus on maintenance hemodialysis. Clin J Am Soc Nephrol (2009) 1.06
Glucose degradation products in PD fluids: do they disappear from the peritoneal cavity and enter the systemic circulation? Kidney Int (2003) 1.06
Novel insights into uremic vascular calcification: role of matrix Gla protein and alpha-2-Heremans Schmid glycoprotein/fetuin. Blood Purif (2002) 1.06
Change in N-terminal-pro-B-type-natriuretic-peptide and the risk of sudden death, stroke, myocardial infarction, and all-cause mortality in diabetic dialysis patients. Eur Heart J (2008) 1.05
National Kidney Foundation consensus conference on cardiovascular and kidney diseases and diabetes risk: an integrated therapeutic approach to reduce events. Kidney Int (2010) 1.04
Homoarginine, cardiovascular risk, and mortality. Circulation (2010) 1.04
Statins, inflammation and kidney disease. Nat Rev Nephrol (2011) 1.04
The association between parathyroid hormone and mortality in dialysis patients is modified by wasting. Nephrol Dial Transplant (2009) 1.04
Changes in adiponectin and the risk of sudden death, stroke, myocardial infarction, and mortality in hemodialysis patients. Kidney Int (2009) 1.03
Gene mutations versus clinically relevant phenotypes: lyso-Gb3 defines Fabry disease. Circ Cardiovasc Genet (2014) 1.03
Survival in patients with high-risk prostate cancer is predicted by miR-221, which regulates proliferation, apoptosis, and invasion of prostate cancer cells by inhibiting IRF2 and SOCS3. Cancer Res (2014) 1.02
Dialyzer membrane characteristics and outcome of patients with type 2 diabetes on maintenance hemodialysis. Am J Kidney Dis (2007) 1.02
Testis-sparing surgery versus radical orchiectomy in patients with Leydig cell tumors. Urology (2009) 1.02
Ventral onlay urethroplasty using buccal mucosa for complex stricture repair. Urology (2003) 1.01
Deficiencies of calcium-regulatory proteins in dialysis patients: a novel concept of cardiovascular calcification in uremia. Kidney Int Suppl (2003) 1.01
Down-regulation of MTUS1 in human colon tumors. Oncol Rep (2010) 1.01
Myeloperoxidase serves as a marker of oxidative stress during single haemodialysis session using two different biocompatible dialysis membranes. Nephrol Dial Transplant (2005) 1.00
Differences in Fabry cardiomyopathy between female and male patients: consequences for diagnostic assessment. JACC Cardiovasc Imaging (2011) 1.00
Solitary schwannoma of the glans penis. Urology (2007) 0.99